Pharmacogenomic profiling of intra-tumor heterogeneity by a large organoid biobank of liver cancer

Mendeley data 1: Immunofluorescence staining of P1 (HCC, shown in Fig. 1D) and P29 (ICC, shown in Data S1.3) organoids. HCC markers (AFP and Hepatocyte) and biliary markers (EPCAM and KRT19) were assayed by immunofluorescence staining, using two organoid cultures of the same passage, due to the limit of three channels (blue, green and red), with overexposure condition applied.
Mendeley data 2: H&E and IHC staining of three tumor regions from a HCC patient P1, and H&E, IHC and immunofluorescence staining of the corresponding organoids. HCC markers (AFP and HepPar1) and biliary markers (EPCAM and KRT19) were assayed by IHC and immunofluorescence staining. Scale bars indicate 50 μm.
Mendeley data 3: H&E and IHC staining of tumor lesions from HCC (A), ICC (B) and CHC (C) patients, and H&E, IHC and immunofluorescence staining of the derived organoids. HCC markers (AFP, HepPar1) and ICC markers (KRT19 and EPCAM) were assayed by IHC and immunofluorescence staining. Scale bars indicate 50 μm.